Macrogenics (MGNX) Change in Receivables (2012 - 2026)
Macrogenics (MGNX) posted quarterly Change in Receivables of -$2.9 million for Q1 2026, down 147.28% year-over-year from $6.2 million in Q1 2025, and up 94.72% quarter-over-quarter from -$55.9 million in Q4 2025.
Macrogenics (MGNX) Change in Receivables (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Change in Receivables for 15 consecutive years, with -$2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 147.28% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at -$117000.0 (down 103.52% YoY), while the FY2025 annual figure was $9.1 million, up 249.6% from the prior year.
- Change in Receivables advanced to -$2.9 million in Q1 2026 per MGNX's latest filing, from -$55.9 million in the prior quarter.
- Across five years, Change in Receivables topped out at $56.7 million in Q3 2025 and bottomed at -$55.9 million in Q4 2025.
- Historically, Change in Receivables has averaged $2294.1 across 5 years, with a median of -$1.0 million in 2024.
- On a YoY basis, Change in Receivables climbed as much as 2114.77% in 2025 and fell as far as 1157.5% in 2025.
- Macrogenics' Change in Receivables stood at $42.4 million in 2022, then slumped by 135.26% to -$14.9 million in 2023, then jumped by 70.28% to -$4.4 million in 2024, then slumped by 1157.5% to -$55.9 million in 2025, then soared by 94.72% to -$2.9 million in 2026.
- Business Quant data shows MGNX's Change in Receivables at -$2.9 million in Q1 2026, -$55.9 million in Q4 2025, and $56.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.95 Mn |
| Mar 31, 2026 | -2.95 Mn |
| Dec 31, 2025 | -55.86 Mn |
| Dec 31, 2025 | -55.86 Mn |
| Sep 30, 2025 | 56.70 Mn |
| Sep 30, 2025 | 56.70 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | 6.23 Mn |
| Mar 31, 2025 | 6.23 Mn |
| Dec 31, 2024 | -4.44 Mn |
| Dec 31, 2024 | -4.44 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -3.15 Mn |
| Mar 31, 2024 | -3.15 Mn |
| Dec 31, 2023 | -14.94 Mn |
| Dec 31, 2023 | -14.94 Mn |